Cardinal Health, Inc.

🇺🇸New York Stock Exchange
Back to all articles
Cardinal Health, Inc. stock analysis CAH overview
Bullish +75

IBD Stock Of The Day: Why Cardinal Health's Momentum Is 'Special' — And Not Over Yet - Investor's Business Daily

📊 Cardinal Health (CAH) is featured as Investor's Business Daily's Stock of the Day, highlighted for its special momentum in the biopharma industry.

💰 The company raised fiscal year 2026 guidance for adjusted earnings to "at least $10" per share, surpassing the previous expectation of $9.65 to $9.85.

📈 Leerink Partners analyst Michael Cherny described the stock's momentum as special and stated that the company is not done delivering positive results.

🚀 Shares jumped nearly 3% on January 13 following the earnings guidance increase, reflecting confidence in ongoing upside drivers.

💊 Cardinal Health expects its specialty products business to generate over $50 billion in sales during fiscal year 2026, which ends June 30.

🧬 Analysts note that the company is investing deeply in its specialty portfolio, specifically targeting oncology, autoimmune, and urology segments.

🚚 The company expanded its at-home business focusing on diabetes care and wearable devices like continuous glucose monitors following the $1.1 billion acquisition of Advanced Diabetes Supply Group.

🤝 Cardinal Health confirmed it has successfully navigated contracting with major pharmaceutical companies to mitigate impacts from price cuts under the Inflation Reduction Act.

🏢 JPMorgan analysts highlighted the expansion of Cardinal's national distribution network with 11 centers designed to scale capacity for continued growth.

⚖️ The stock currently has a Relative Strength Rating of 90, placing its 12-month performance in the top 10% of all stocks on MarketSurge.

📉 While shares recently traded below the January 15 buy point of $214.93, they are rebounding off their 21-day exponential moving average.

👨‍💼 Michael Cherny reiterated an outperform rating, citing confirmed guidance increases and room to grow as evidence of strong performance under current leadership.

🔮 Leerink Partners projects fiscal year 2026 earnings between $11.08 and $11.28 per share, driven primarily by the pharmaceutical business segment.

Bullish Signals
  • Cardinal Health (CAH) received 'IBD Stock Of The Day' recognition, indicating strong technical momentum and positive market sentiment.
  • The company raised its guidance for fiscal year 2026 adjusted earnings to at least $10 per share, up from a previous expectation of $9.65-$9.85.
  • Specialty products are forecasted to generate more than $50 billion in sales during fiscal year 2026, signaling sustained demand and growth potential.
  • Analyst Michael Cherny projects fiscal year 2026 earnings could reach $11.08-$11.28 per share, driven largely by the pharma business.
  • JPMorgan analysts highlight deep investment in specialty segments including oncology, autoimmune, and urology with expectations for above-trend revenue growth.
  • The at-Home Solutions business is forecast to bring in $1 billion in fiscal year 2028 sales, representing a 20% CAGR with significant 30% growth projected for 2026.
  • Cardinal Health has expanded its national network of 11 distribution centers to scale capacity for continued at-home solution growth.
  • The company successfully navigated contracting challenges under the Inflation Reduction Act, easing concerns about pricing impacts on distributors.
  • Acquisition of Advanced Diabetes Supply Group for $1.1 billion and a partnership with Publix are strengthening the at-home business focused on diabetes care.
  • Cardinal Health achieved a strong Relative Strength Rating of 90, placing its 12-month performance in the top 10% of all stocks.
Risk Factors
  • Cardinal Health shares have recently fallen below the technical breakout buy point of $214.93, indicating a failed attempt to break out from its flat base pattern.
  • The company raised its fiscal year 2026 earnings guidance by only 2.5%, which suggests limited upside potential from what was already expected by analysts.
Full Analysis
Cardinal Health (CAH) is featured as the Investor's Business Daily Stock of the Day, highlighted for its strong technical momentum and positive business developments. The company, a major drug wholesaler serving pharmacies, hospitals, and clinics, recently raised its guidance for fiscal year 2026, projecting adjusted earnings of "at least $10" per share, up from the previous expectation of $9.65 to $9.85. Analyst Michael Cherny at Leerink Partners praised this guidance increase as a confirmation of ongoing upside drivers, noting that even accounting for the uptick, there remains significant potential with the higher earnings floor. Key growth drivers include deep investment in Cardinal's specialty business, particularly in oncology and autoimmune therapies, where it expects above-trend revenue growth to continue through fiscal 2028 with a forecasted sales figure of $1 billion. This specialty segment is expected to grow at a 30% compound annual rate in 2026 alone. Additionally, Cardinal is expanding its at-home business, specifically focusing on diabetes care and wearable devices like continuous glucose monitors, bolstered by a partnership with grocery chain Publix and the recent $1.1 billion acquisition of Advanced Diabetes Supply Group. Analysts also view Cardinal's ability to navigate pricing pressures under the Inflation Reduction Act favorably. While pharmaceutical companies face price negotiations that could impact their sales, Cardinal's diversified model and strong relationships help mitigate concerns about how distributors will be affected by drug price cuts. Technical analysis supports this bullish outlook, with the stock showing a relative strength rating of 90 and recent performance placing it in the top 10% over its 12-month history, though shares have recently dipped below a specific buy point at $214.93 following their rise off the 21-day exponential moving average.